True Wealth Design’s Vanda Pharmaceuticals VNDA Stock Holding History

True Wealth Design’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.72K	Sell	758 -569	-43%	-$3.06K	﹤0.01%	1450
2026 Q2	$8.12K	Buy	1,327 +602	+83%	+$3.93K	﹤0.01%	1146
2026 Q1	$5.01K	Buy	725 +206	+40%	+$1.59K	﹤0.01%	1206
2025 Q4	$4.58K	Sell	519 -11	-2%	-$61	﹤0.01%	1120
2025 Q3	$2.65K	Buy	530 +102	+24%	+$472	﹤0.01%	1368
2025 Q2	$2.02K	Buy	428 +420	+5,250%	+$1.84K	﹤0.01%	1182
2025 Q1	$37	Sell	8 -17	-68%	-$79	﹤0.01%	2462
2024 Q4	$120	Buy	+25	New	+$120	﹤0.01%	1269

Other funds holding VNDA

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

CFS

CGC Financial Services Lake Oswego, Oregon $451M AUM 11.72% 1-Year Est. Return

True Wealth Design's VNDA Position: Q3 2026 in Review

True Wealth Design reduced its Vanda Pharmaceuticals (VNDA) stake by 43% in Q3 2026, selling an estimated $3.06K and leaving 758 shares worth $3.72K. The position accounts for ﹤0.01% of the portfolio, ranked #1450.

True Wealth Design first reported a position in VNDA in Q4 2024 and has held it in 8 quarters since. The position peaked at $8.12K in Q2 2026. 9 funds tracked by Wall St. Rank hold VNDA as of Q3 2026.

True Wealth Design held 758 shares of Vanda Pharmaceuticals worth $3.72K as of Q3 2026.
True Wealth Design sold 569 Vanda Pharmaceuticals shares in Q3 2026, an estimated $3.06K.
Vanda Pharmaceuticals made up ﹤0.01% of True Wealth Design's portfolio in Q3 2026, its #1450 holding.
True Wealth Design first reported a position in Vanda Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
True Wealth Design's Vanda Pharmaceuticals position peaked at $8.12K in Q2 2026.
9 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.